Blog Case Study

63 次迭代仍未收敛：When RsNLME Succeeded Where Other PK/PD Solutions Couldn’t

After 63 failed runs on a 16-ODE neutropenia model, RsNLME achieved PK/PD convergence on the…

Stephen Duffull2026 年 6 月 23 日

Poster

Machine Learning-Based Covariate Selection for Population Pharmacokinetic Modeling

Authors: Ibtissem Rebai (Certara), Stephen Duffull (Certara), Ayman Akil (Certara), Anna Largajolli (Certara), Floris Fauchet…

Certara2026 年 6 月 22 日

Poster

Shaping the future of AI/ML in pharmacometrics through collaboration, education and best practices

Discover how the AI/ML Special Interest Group is advancing responsible artificial intelligence in pharmacometrics through…

Certara2026 年 6 月 22 日

Webinar

Model Smarter, Not Harder: Introducing Model Designer

2026 年 6 月 30 日, 10:00 – 11:00 AM ET | 2026 年 7 月 2 日, 10:00 – 11:00…

Danielle Pillsbury2026 年 6 月 10 日

Poster

Translating Targeted Radiotherapies from Mouse to Human Using QSP: A Pluvicto Case Study

Download this poster to see how Certara used quantitative systems pharmacology (QSP) to translate ¹⁷⁷Lu-PSMA-617…

Certara2026 年 6 月 9 日

Poster

Population Pharmacokinetic Modeling to Predict Absorbed and Biologically Effective Dose for Radioligand Therapies

Explore how population PK modeling predicts absorbed dose and biologically effective dose for radioligand therapies.

Certara2026 年 6 月 9 日

Blog

Beyond Compliance: What ICH M15 Means for the Future of Drug Development

Explore how ICH M15 is shaping regulatory expectations for Model-Informed Drug Development (MIDD), including model…

Certara2026 年 6 月 9 日

Video

Applying AI-Driven Biosimulation to Drug Discovery

Certara President Leif Pedersen explains how PBPK and QSP modeling, proven across 125+ FDA-approved drugs,…

Certara2026 年 6 月 2 日

Publication

Oxford Academic, Neuro-Oncology Pediatrics – BRAF pub: Growth recovery in patients with BRAF-altered pediatric low-grade glioma following treatment with tovorafenib

This publication reports a pooled retrospective analysis evaluating growth patterns in children with B-Raf proto-oncogene…

Dorottya Gui-Bodnar2026 年 5 月 28 日

Blog

Certainty US 2026 recap: advancing model-informed drug development right from the start

This blog shares the highlights of our US Certainty event and explains how AI-enabled approaches…

Certara2026 年 5 月 26 日

Modeling and Simulation – PK/PD

63 次迭代仍未收敛：When RsNLME Succeeded Where Other PK/PD Solutions Couldn’t

Machine Learning-Based Covariate Selection for Population Pharmacokinetic Modeling

Shaping the future of AI/ML in pharmacometrics through collaboration, education and best practices

Model Smarter, Not Harder: Introducing Model Designer

Translating Targeted Radiotherapies from Mouse to Human Using QSP: A Pluvicto Case Study

Population Pharmacokinetic Modeling to Predict Absorbed and Biologically Effective Dose for Radioligand Therapies

Beyond Compliance: What ICH M15 Means for the Future of Drug Development

Applying AI-Driven Biosimulation to Drug Discovery

Oxford Academic, Neuro-Oncology Pediatrics – BRAF pub: Growth recovery in patients with BRAF-altered pediatric low-grade glioma following treatment with tovorafenib

Certainty US 2026 recap: advancing model-informed drug development right from the start

订阅时事通讯

快捷链接

解决方案

联系我们